Clinical Trials

There
are 41 clinical trials
for peripheral T-cell lymphoma, of which 36
are
open and 5
are
completed or closed.
Of the
trials that contain
peripheral T-cell lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 16 are phase 1 (11 open), 7 are phase 1/phase 2 (7 open), 14 are phase 2 (14 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).

Significant Genes in Peripheral T-Cell Lymphoma

ABL1
+

ABL1 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
ABL1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

AFF1
+

AFF1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
AFF1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
ASXL1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

BCL2
+

BCL2 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
BCL2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR
+

BCR is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
BCR status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

CD274
+

CD274 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
CD274 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK
+

DEK is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
DEK status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

ELL
+

ELL is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
ELL status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ETV6
+

ETV6 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
ETV6 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FLT3
+

FLT3 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
FLT3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

HRAS
+

HRAS is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
HRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

IRAK1
+

IRAK1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
IRAK1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK2
+

JAK2 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
JAK2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
JAK3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A
+

KMT2A is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
KMT2A status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

KRAS
+

KRAS is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
KRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
MECOM status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

MLLT1
+

MLLT1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10
+

MLLT10 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT10 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3
+

MLLT3 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4
+

MLLT4 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT4 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC
+

MYC is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MYC status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYD88
+

MYD88 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MYD88 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRAS
+

NRAS is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
NRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NUP214
+

NUP214 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
NUP214 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

PBX1
+

PBX1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
PBX1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1
+

RPN1 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
RPN1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

RUNX1
+

RUNX1 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
RUNX1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

TCF3
+

TCF3 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
TCF3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical
trials
for peripheral T-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
TP53 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

TYK2
+

TYK2 is an inclusion eligibility criterion in 1 clinical
trial
for peripheral T-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
TYK2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

Disease Details

Parent(s)

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.